The U.S. Centers for Disease Control and Prevention has identified a total of 216 cases of cardiac inflammation after the first dose of an mRNA stroke, and another 573 cases after the second dose.
U.S. public health advisers met to discuss a potential link between Covid-19 strokes using RNA messenger technology and inflammation of the heart after hundreds of vaccinators had a condition called myocarditis.
The Advisory Board of the Centers for Disease Control and Prevention on Immunization Practices will meet on June 18 to discuss an increase in reported cases of the disease, particularly among adolescents and young adults. Covid vaccines made by Moderna Inc. and Pfizer Inc. partners. and BioNTech SE use mRNA technology.
Since April, the CDC has seen an increase in reports of myocarditis with pericarditis, an inflammation of the membrane around the heart. Cases, although rare, occur mainly in adolescent males and young adults.
The CDC has identified a total of 216 cases of cardiac inflammation after the first dose of an mRNA stroke, and another 573 cases after the second dose. The mean age of people with myocarditis or pericarditis after the first dose was 30, and 24 between the second dose cases. There were 475 cases identified among those under 30 years of age.
Most patients responded well to treatment and rest, according to the agency, and more than 8 in 10 had full relief from their symptoms. The agency further examines cases by age.
About 130 million Americans received the full two-dose regimen of one of two authorized mRNA vaccines. Many teens have now received their first dose of the Pfizer-BioNTech vaccine, which was released for teens 12 years or older on May 10th.
“We’re still learning about myocarditis and pericarditis rates,” Tom Shimabukuro, a security expert at the CDC National Center for Emerging and Zoonotic Infectious Diseases, said Thursday at a meeting of the Food and Drug Administration a Drug Administration. “As we gather more information, we will begin to have a better idea of post-vaccination rates and hope to be able to obtain more detailed information by age groups.”
Shimabukuro said U.S. data is consistent with results from Israel’s vaccinated population.
“It’s hard to deny that there are any events that seem to have happened,” Cody Meissner, head of the Division of Pediatric Infectious Diseases at Tufts Medical Center, said at the FDA advisory committee meeting Thursday.